GlobalData on MSN17h
Viking stock fluctuates amid manufacturing concerns with obesity pill
Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...
Why Viking Therapeutics Stock Plummeted After Soaring Today
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Viking Therapeutics (VKTX) Gets a Buy from Truist Financial
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
Should you buy Viking Therapeutics (VKTX) after today’s spike?
Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.
The Motley Fool on MSN22h
Is Viking Therepautics a Buy Now?
The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.
Hosted on MSN1d
Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat
Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...